REFERENCES

1. Ali S, Mann DA. Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct 2004;22:67–79.
2. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32: 980–986.
3. Bianchi C and Franceschini J. Experimental observations on Haffner’s method for testing analgesic drugs. Brit. J. Pharmacol.1954; 9, 280.
4. Burke A., Smyth E, FitzGerald G. Analgesic-antipyretic and anti-inflammatory agents: Pharmacotherapy of Gout, ed Brunton LL, Lazo JS, Parker KL, Goodman and Gilman’s The Pharmacologic Basis of Therapeutics, 11th edition, 2006, McGraw Hill Publications, New York : 671- 715.
5. Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 2000; 36: 923–928.
6. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A–28A.
7. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991; 104: 765–767.
8. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992; 107: 660–664.
9. Cunha TM, Verri Jr WA, Silva JS, Poole S, Cunha FQ, Ferreira SH. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA, 2005; 102: 1755–1760.
10. Duarte ID, Santos IR, Lorenzetti BB, Ferreira SH. Analgesia by direct antagonism of nociceptor sensitization involves the arginine–nitric oxide–cGMP pathway. Eur J Pharmacol 1992; 217: 225–227.
11. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA, 1998; 95: 8880–8885.
12. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature.1988;334: 698–700.
13. Ferreira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol. 1993;110: 1227–1231.
14. Ferreira SH, Nakamura MI – Prostaglandin hyperalgesia, a cAMP/Ca^2± dependent process. Prostaglandins, Br J Pharmacol 1979;18: 179–190.
15. Gomez-Hernandez A, Sanchez-Galan E, Martin-Ventura JL, Vidal C, Blanco-Colio LM, Ortego M et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol. 2006;47: 60–69.
16. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101: 2711–2719.
17. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther, 2003;41: 397–401.
18. Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol. 1999; 81: 1104–1112.
19. Kumar V, Abbas AK, Fausto N, Acute and chronic inflammation, in Robbins and Cotrans, Pathologic Basis of Disease, 7^th edition, 2004, Elsevier publication, Pennysylvania: 47-86.
20. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998; 273: 24266–24271.
21. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002; 2: 725–734.
22. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull .2005; 28: 1630–1634.
23. Lorenzetti BB, Veiga FH, Canetti CA, Poole S, Cunha FQ, Ferreira SH. Cytokine-induced neutrophil chemoattractant-1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivity in rats. Eur Cytokine Network. 2002; 13: 456–461.
24. McCarey DW, Mclnnes IB, Madhok R, Hampson R, Scherbakova O, Ford I et al. Trial of Atrovastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. The Lancet 2004; 363:2015-2020.
25. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1–164.
26. Nakamura M, Ferreira SH. A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol. 1987; 135: 145–153.
27. Planavila A, Laguna JC, Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta 2005; 1687: 76–83.
28. Prasad R, Giri S, Nath N, Singh I, Singh AK. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial–monocyte cell interaction. J Neurochem 2005; 94: 204–214.
29.  Santodomingo-Garzon T, Cunha TM, Vern WA , Valerio DAR, Parada CA, Poole S, Ferreira SH and Cunha. FQ Atorvastatin inhibits inflammatory hypernociception. British Journal of Pharmacology 2006; 149, 14-22.
30. Schmidt GW. Statins as anti-inflammatory agents. Trends in Pharmacological Sciences. 2002; 23:482-486.
31. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood–brain barrier. J Nutr Health Aging 2002;6: 324–331.
32. Taiwo YO, Bjerknes LK, Goetzl EJ, Levine JD Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 1989;32: 577–580.
33. Tondon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Ind J. Pharmacol 2005;37:77-85
34. Wu KK. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 89–93.
35. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78–84.